The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism.
J C Byrd; C Shinn; C R Willis; I W Flinn; T Lehman; E Sausville; D Lucas; M R Grever (Profiled Author: Edward A Sausville)
Division of Hematology-Oncology, Walter Reed Army Medical Center, Washington, DC, USA. firstname.lastname@example.org
Experimental hematology 2001;29(6):703-8.
OBJECTIVES: UCN-01, a novel protein kinase C inhibitor, is currently being tested in phase I clinical trials after being noted to induce apoptosis in lymphoid cell lines. We sought to study the in vitro activity of UCN-01 against human chronic lymphocytic leukemia (CLL) cells and potential mechanisms of action for inducing this cytotoxicity. METHODS: Detailed in vitro studies were performed from tumor cells derived from patients with CLL cells following attainment of written informed consent. RESULTS: The 50% loss of viability (LC(50)) in mononuclear cells from CLL patients (n = 10) following exposure to UCN-01 for 4 days was 0.4 microM (95% CI +/- 0.21; range 0.09-1.16). Loss of viability in human CLL cells correlated with early induction of apoptosis. Exposure of CLL cells to 0.4 and 5.0 microM of UCN-01 resulted in decreased expression of p53 protein. We therefore investigated the dependence of UCN-01 on intact p53 by exposing splenocytes from wild-type (p53(+/+)) and p53 null (p53(-/-)) mice, which demonstrated no preferential cytotoxicity when compared to the marked differential induced by F-Ara-A and radiation. CONCLUSIONS: UCN-01 has significant in vitro activity against human CLL cells that appears to occur independent of p53 status. While demonstration of in vitro cytotoxicity does not establish in vivo efficacy, the findings described support the early introduction of UCN-01 into clinical trials for patients with B-CLL.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
J C Byrd; C Shinn; J K Waselenko; E J Fuchs; T A Lehman; P L Nguyen; I W Flinn; L F Diehl; E Sausville; M R GreverBlood 1998;92(10):3804-16.
Alexander G Yakovlev; Simone Di Giovanni; Geping Wang; Wenfan Liu; Bogdan Stoica; Alan I FadenThe Journal of biological chemistry 2004;279(27):28367-74.
P C Mack; D R Gandara; C Bowen; M J Edelman; T Paglieroni; J B Schnier; E P Gelmann; P H GumerlockClinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2596-604.
Appears in this Publication
Author of this Publication